5 Best Affordable Stocks Under $30

1. Viatris Inc. (NASDAQ:VTRS)

Price as of December 01: $10.97

Forward P/E ratio as of December 01: 3.39

Number of Hedge Fund Holders: 50

Viatris Inc. (NASDAQ:VTRS) is a multinational pharmaceutical and healthcare company based in the United States. The business is divided into Developed Markets, Greater China, JANZ, and Emerging Markets. Viatris Inc. (NASDAQ:VTRS) provides prescription brand medications, generic medications, complex generic medications, biosimilars, and active pharmaceutical components.

On November 07, 2022, Viatris Inc. (NASDAQ:VTRS) reported results for Q3 2022, posting revenue of $4.07 billion for the quarter, missing the market estimate by $70 million. The company’s Normalized EPS of $0.87 beat the market estimate by $0.04.

50 hedge funds are currently bullish on Viatris Inc. (NASDAQ:VTRS) as per Insider Monkey’s database. Camber Capital Management had the leading stake in the company at the end of Q3 2022.

Miller Value Partners mentioned Viatris Inc. (NASDAQ:VTRS) in its recently-published Q3 2022 investor letter. Here is what the firm has to say:

Viatris Inc. (NASDAQ:VTRS) fell 17.8%² during the quarter. Viatris reported 2Q22 revenue of $4.12 billion, -3% Y/Y on an operational basis, below consensus of $4.19 billion, and diluted EPS of $0.26, compared to a net loss per share of -$0.23 in 2Q21, ahead of analyst expectations for EPS of $0.19. The company generated 2Q22 FCF of $718.6 million, bringing TTM FCF to $3,082.9 million, or a FCF yield of 26.6%. In the 1H22, Viatris retired $1.5 billion in debt, which puts the company well on track to achieve its FY22 debt paydown target of $2.0 billion. While the company lowered FY22 revenue guidance to be in a range of $16.2-16.7 billion, compared to previous guidance for revenue of $17-17.5 billion, this revision is solely attributable to the incremental impact of FX headwinds. The company reaffirmed FY22 guidance for Adjusted EBITDA of $5.8-6.2 billion (36.5% margin at midpoint) and FCF of $2.5-2.9 billion, or a forward FCF yield of 23.3%. The company generated approximately $84 million in new product revenues in 2Q22, bringing 1H22 revenues to $205 million, which were primarily driven by interchangeable Semglee in the US, and the company remains on track to achieve ~$600 million (3.7% of FY22 guided revenue at the midpoint) in FY22 new product revenues.

You can also take a look at 15 Biggest Jewelry Companies in the World and 15 Biggest Holding Companies in the World.

Follow Insider Monkey on Twitter